Project Grant R50CA305109
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $882K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, EE. UU.
Similar Awards
- The National Cancer Institute (NCI) awarded a $220,340 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine, effective July 31, 2024 through March 31, 2025. The grant supports a research project titled "Targeting the RNA Helicase DDX6 in Acute Myeloid Leukemia". The project aims to conduct innovative research on acute myeloid leukemia (AML), an aggressive blood cancer, with a focus on understanding the role of the RNA helicase DDX6 and developing new...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,759,500.00 to Baylor College of Medicine in Houston, Texas to support research aimed at "Creating Cures for Patients with Langerhans Cell Histiocytosis." The award, which runs from September 1, 2024 to August 31, 2028, will enable Baylor to conduct innovative biomedical studies to develop new treatments and therapies for this rare genetic...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This $147,486 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by Baylor College of Medicine to investigate the role of the HP1BP3 protein in regulating chromatin remodeling and its impact on tumor growth in high-grade glioma, the most common malignant adult brain cancer. The research aims to define epigenomic dysregulations that promote glioma growth and determine the mechanisms by which these alterations drive tumorigenesis....
- The federal Project Grant award of $1,597,224.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to support the research project "BCL-XL IN BREAST CANCER METASTASIS AND THERAPY" at Baylor College of Medicine in Houston, Texas. The award, with a performance period from August 1, 2024 to July 31, 2027, will fund advanced biomedical research initiatives focused on transforming healthcare for military service...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $197,518 to The Children's Hospital of Philadelphia (CHOP) to address barriers to conducting clinical trials for patients with rare tumors. The awardee, who serves as Chair of the Children's Oncology Group (COG) Rare Tumor Disease Committee and Study Chair for three COG clinical trials, will use the funding to: Expand the availability of rare tumor clinical trials within COG,...
- This federal Project Grant award of $2,239,998.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate the progression from ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer driven by the N-RAS gene. The research project aims to advance the understanding of this disease process with the potential to lead to improved diagnostic and treatment approaches. The award...
- The University of Texas MD Anderson Cancer Center received a $1,824,620 Project Grant award from the National Institutes of Health's National Cancer Institute (CFDA 93.397 - Cancer Centers Support Grants) to reduce morbidity and mortality from sarcomas through innovative translational research focused on immunologic and targeted treatments. Key project activities include: Developing an effective systemic adoptive cellular therapy platform for chordoma patients by pursuing a clinical trial of...
- The National Cancer Institute (NCI) awarded a $678,723 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Baylor College of Medicine, located in Texas, USA. The project aims to ascertain the pathobiological role and translational significance of non-proteolytic ubiquitination of Programmed Death Ligand 1 (PD-L1) in evading tumoricidal T cells and improving cancer care, with a focus on lung cancer. The award period extends from February 21, 2025 to January 31, 2030....